49,05 kr
−0,91 % i dag
Siste registrerte kurs: 13. okt., 16:25. Hentet: 14. okt., 02:25. Tid i Oslo. Kilde: Yahoo Finance. Kursene kan være forsinket.
1,32 mrd. kr
33 669
+2,70 %
Siste 12 måneder · tall i NOK
Kilde: Yahoo Finance. Ikke en anbefaling fra oss.
Photocure ASA er et selskap innen helse og bioteknologi notert på Oslo Børs med tickeren PHO. Hovedkontoret ligger i Oslo, Norge. Selskapet har 99 ansatte.
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. It has partnership with Artera for digital pathology AI test evaluation for bladder cancer. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, other European countries, Canada, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Beskrivelse på engelsk fra Yahoo Finance.
Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II
Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S.
Photocure ASA: Notification of primary insider transactions
Photocure ASA - Share option grant to members of the board of directors
Photocure ASA: Asieris counterclaim on milestone payment arbitration
Photocure ASA - Share option grant
Photocure ASA: Results for the second quarter of 2026
Photocure ASA: Invitation to presentation of second quarter 2026 financial results
Photocure ASA - Share option grant
Photocure ASA - CFO transition
Siste tilgjengelige kurs for Photocure ASA (PHO) er 49,05 kr, en endring på −0,91 % siste handelsdag. Kilde: Yahoo Finance. Kursene på Finansparken kan være forsinket med 15 minutter eller mer.
Photocure ASA er notert på Oslo Børs med tickeren PHO. ISIN-koden er NO0010000045. Aksjen kan handles gjennom banker og nettmeglere som tilbyr handel på Oslo Børs.
Markedsverdien til Photocure ASA er 1,32 mrd. kr, beregnet som aksjekursen ganget med antall utestående aksjer. Det gjør selskapet til nummer 164 av 293 aksjer i Oslo målt etter markedsverdi.
Photocure ASA er plassert i sektoren Helse og bioteknologi (bransje: Drug Manufacturers - Specialty & Generic). På sektorsiden finner du alle aksjer i samme sektor.
Medistim ASA
MEDI · 5,21 mrd. kr
285,00 kr
+0,71 %
Circio Holding ASA
CRNA · 3,18 mrd. kr
10,92 kr
−1,09 %
Nordhealth AS
NORDH · 2,21 mrd. kr
28,00 kr
0,00 %
Thor Medical ASA
TRMED · 1,84 mrd. kr
4,36 kr
−1,58 %
Nykode Therapeutics AS
NYKD · 1,25 mrd. kr
3,205 kr
−6,15 %
ArcticZymes Technologies ASA
AZT · 980,6 mill. kr
19,20 kr
+0,26 %